Corporate ActionOct 19, 2026, 08:51 AM
OS Therapies Raises $7.2M in Initial Warrant Exercise Closing
AI Summary
OS Therapies Inc. announced the initial closing of its warrant exercise inducement and exchange offer, raising approximately $7.2 million in gross proceeds. Seven investors exercised or pre-funded warrants to purchase 5,517,253 shares of common stock, in exchange for which the company issued new warrants for the same number of shares. The offer, which allows for a reduced exercise price of $1.30 per share, is expected to yield up to $12.3 million if fully subscribed. The funds will be used for regulatory submissions and commercial preparations for its lead asset, Herlystic™, and for general corporate purposes. The company also noted $7 million in accrued UK R&D tax credits.
Key Highlights
- OS Therapies Inc. completed an initial closing of its warrant exercise inducement and exchange offer, raising approximately $7.2 million in gross proceeds.
- Seven accredited investors exercised or pre-funded warrants to purchase 5,517,253 shares of common stock.
- The company issued new warrants to purchase an equal number of shares (5,517,253) at an exercise price of $1.40 per share.
- The offer allows for exercise at a reduced price of $1.30 per share, with an option to pre-fund at $1.299 per share.
- The company expects to receive up to $12.3 million if all outstanding warrants are exercised or pre-funded.
- Proceeds will support regulatory filings and commercial preparation for Herlystic™ (OST-HER2) and general corporate purposes.
- The company has accrued $7 million in refundable UK R&D tax credits, expected in early 2027.
Price Impact
More from OSTX